47 results found.

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using MV-NIS; cyclophosphamide; I-123 prior MV-NIS; I-123 post MV-NIS; Liothyronine

Mayo Clinic - Recruiting 18 years or older.
- Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma.
MV-NIS; cyclophosphamide; I-123 prior MV-NIS; I-123 post MV-NIS; Liothyronine

Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II M Clinical Trial using carfilzomib; dexamethasone; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2).
carfilzomib; dexamethasone; laboratory biomarker analysis

Myeloma Clinical Trial using Pomalidomide; Dexamethasone; G-CSF; Phone Calls

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma.
Pomalidomide; Dexamethasone; G-CSF; Phone Calls

Multiple Myeloma Clinical Trial using lenalidomide; pidilizumab; pharmacological study; laboratory biomarker analysis

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma.
lenalidomide; pidilizumab; pharmacological study; laboratory biomarker analysis

Multiple Myeloma Clinical Trial using DFRF4539A

Genentech - Recruiting 18 years or older.
- An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma.
DFRF4539A

Refractory Multiple Myeloma Clinical Trial using pomalidomide; bortezomib; dexamethasone; laboratory biomarker analysis; gene expression analysis

Mayo Clinic - Recruiting 18 years or older.
- MC1082: A Phase I/II Trial of Pomalidomide (CC-4047), Bortezomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
pomalidomide; bortezomib; dexamethasone; laboratory biomarker analysis; gene expression analysis

Refractory Multiple Myeloma Clinical Trial using bendamustine hydrochloride; lenalidomide; dexamethasone

Mayo Clinic - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label, Dose-escalation Study of Bendamustine in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
bendamustine hydrochloride; lenalidomide; dexamethasone

Multiple Myeloma Clinical Trial using Daratumumab; Lenalidomide; Dexamethasone

Genmab - Recruiting 18 years or older.
- An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma.
Daratumumab; Lenalidomide; Dexamethasone

Relapsed/Refractory Multiple Myeloma Clinical Trial using plitidepsin + dexamethasone; dexamethasone

PharmaMar - Recruiting 18 years or older.
- Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma.
plitidepsin + dexamethasone; dexamethasone

Multiple Myeloma Clinical Trial using carfilzomib and panobinostat

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma.
carfilzomib and panobinostat

Multiple Myeloma Clinical Trial using Daratumumab 16 mg/kg (Part 1); Daratumumab 8 mg/kg (Part 1); Methylprednisolone; Acetaminophen; Diphenhydramine; Daratumumab (Part 2)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD.
Daratumumab 16 mg/kg (Part 1); Daratumumab 8 mg/kg (Part 1); Methylprednisolone; Acetaminophen; Diphenhydramine; Daratumumab (Part 2)

Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Mac Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies.
CB-839

Myeloma Clinical Trial using Arry-520; Carfilzomib; Dexamethasone; Filgrastim

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma.
Arry-520; Carfilzomib; Dexamethasone; Filgrastim

Multiple Myeloma Clinical Trial using 4 mg Oral POM + 40 mg Oral DEX; 2 mg Oral POM + 40 mg Oral DEX

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics (PK) and Safety of Pomalidomide (POM) When Given in Combination With Low Dose Dexamethasone (LD-DEX) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Impaired Renal Function.
4 mg Oral POM + 40 mg Oral DEX; 2 mg Oral POM + 40 mg Oral DEX

Multiple Myeloma Clinical Trial using Pomalidomide; stem cell; Dexamethasone; Clarithromycin

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Autologous Stem Cell Transplant With Pomalidomide (CC-4047r) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium.
Pomalidomide; stem cell; Dexamethasone; Clarithromycin

Multiple Myeloma Clinical Trial using SAR650984; Lenalidomide

Sanofi - Recruiting 18 years or older.
- A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
SAR650984; Lenalidomide

Multiple Myeloma Clinical Trial using Bendamustine; Doxorubicin; Bortezomib; Filgrastim

Hoosier Oncology Group - Recruiting 18 years or older.
- A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma.
Bendamustine; Doxorubicin; Bortezomib; Filgrastim

Myeloma Clinical Trial using Carfilzomib; Panobinostat

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat Plus Carfilzomib in Patients With Relapsed/Refractory Myeloma.
Carfilzomib; Panobinostat

Multiple Myeloma Clinical Trial using Panobinostat; Carfilzomib; Dexamethasone

Emory University - Recruiting 18 years or older.
- A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma.
Panobinostat; Carfilzomib; Dexamethasone

Relapsed and/or Refractory Multiple Myeloma Clinical Trial using Elotuzumab; Thalidomide; Dexamethasone; Cyclophosphamide

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 2a Single-Arm Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma.
Elotuzumab; Thalidomide; Dexamethasone; Cyclophosphamide

Multiple Myeloma Clinical Trial using Anti-CXCR4 (BMS-936564); Lenalidomide; Dexamethasone; Bortezomib

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.
Anti-CXCR4 (BMS-936564); Lenalidomide; Dexamethasone; Bortezomib

Multiple Myeloma Clinical Trial using Ibrutinib; Carfilzomib; Placebo

Pharmacyclics - Recruiting 18 years or older.
- A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (KyprolisT) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma.
Ibrutinib; Carfilzomib; Placebo

Multiple Myeloma Clinical Trial using Oprozomib; Pomalidomide; Dexamethasone

Onyx Pharmaceuticals - Recruiting 18 years or older.
- Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects.
Oprozomib; Pomalidomide; Dexamethasone

Multiple Myeloma, Relapsed, or Multiple Myeloma, Refractory to St Clinical Trial using Total Marrow Irradiation; Melphalan; Filgrastim (G-CSF)

University of Illinois at Chicago - Recruiting 18 years to 75 years.
- BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma.
Total Marrow Irradiation; Melphalan; Filgrastim (G-CSF)

Multiple Myeloma, Plasma Cell Leukemia Clinical Trial using ARRY-520, KSP(Eg5) inhibitor; intravenous; Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Dexamethasone, steroid; oral; Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Array BioPharma - Recruiting 18 years or older.
- .
ARRY-520, KSP(Eg5) inhibitor; intravenous; Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Dexamethasone, steroid; oral; Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy.
Nivolumab

Multiple Myeloma Clinical Trial using Pomalidomide; Bortezomib; Dexamethasone

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.
Pomalidomide; Bortezomib; Dexamethasone

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using bortezomib; dexamethasone

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy.
bortezomib; dexamethasone

Multiple Myeloma Clinical Trial using Bendamustine; Pomalidomide; Dexamethasone

Duke University - Recruiting 18 years or older.
- A Phase I-II Study of the Combination of Bendamustine and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Bendamustine; Pomalidomide; Dexamethasone

Multiple Myeloma Clinical Trial using busulfan; melphalan; fludarabine; anti-thymocyte globulin (ATG); a T cell depleted stem cell transplant

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years to 69 years.
- A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma.
busulfan; melphalan; fludarabine; anti-thymocyte globulin (ATG); a T cell depleted stem cell transplant

Relapsed/Refractory Multiple Myeloma Clinical Trial using ABT-199

AbbVie - Recruiting 18 years or older.
- A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma.
ABT-199

Multiple Myeloma Clinical Trial using Oprozomib; Dexamethasone

Onyx Pharmaceuticals - Recruiting 18 years or older.
- Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Oprozomib; Dexamethasone

Refractory Multiple Myeloma Clinical Trial using carfilzomib; dexamethasone; laboratory biomarker analysis

Indiana University - Recruiting 18 years or older.
- A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy.
carfilzomib; dexamethasone; laboratory biomarker analysis

Multiple Myeloma Clinical Trial using DKN-01 300 mg; DKN-01 600 mg; Standard of Care

Dekkun Corporation - Recruiting 30 years or older.
- A Pilot Study of DKN-01 and Lenalidomide (Revlimidr)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
DKN-01 300 mg; DKN-01 600 mg; Standard of Care

Multiple Myeloma Clinical Trial using PCI-32765; Dexamethasone

Pharmacyclics - Recruiting 18 years or older.
- A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma.
PCI-32765; Dexamethasone

Multiple Myeloma Clinical Trial using Subcutaneous bortezomib

Oncotherapeutics - Recruiting 18 years or older.
- A Phase II Study of Subcutaneous (SC) Bortezomib-Regimens for Patients With Relapsed/Refractory Multiple Myeloma (MM) Failing Prior Intravenous (IV) Bortezomib-Containing Regimens.
Subcutaneous bortezomib

Relapsed or Refractory Multiple Myeloma Clinical Trial using dexamethasone; carfilzomib

Southwest Oncology Group - Recruiting 18 years or older.
- S1304, A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease.
dexamethasone; carfilzomib

Multiple Myeloma Clinical Trial using MLN9708

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1 Pharmacokinetic Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Asian Patients With Multiple Myeloma.
MLN9708

Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II M Clinical Trial using romiplostim

New York University School of Medicine - Recruiting 18 years or older.
- Phase II Trial Evaluating the Efficacy and Safety of Romiplostim (Nplate) Treatment of Chemotherapy Induced Thrombocytopenia in Patients With Multiple Myeloma.
romiplostim

Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multipl Clinical Trial using SNS01-T

Senesco Technologies, Inc. - Recruiting 18 years or older.
- Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma.
SNS01-T

Multiple Myeloma Clinical Trial using PRLX 93936

Prolexys Pharmaceuticals - Recruiting 18 years or older.
- Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma.
PRLX 93936

Multiple Myeloma Clinical Trial using NPI-0052

Triphase Research and Development I Corporation - Recruiting 18 years or older.
- Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma.
NPI-0052

Multiple Myeloma Clinical Trial using masitinib 6 mg/kg/day; placebo

AB Science - Recruiting 18 years or older.
- A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase 3 Study to Compare Efficacy and Safety of Masitinib 6 mg/kg/Day in Combination With Bortezomib and Dexamethasone to Placebo in Combination With Bortezomib and Dexamethasone in the Treatment of Patients With Relapsing Multiple Myeloma Who Received One Previous Therapy.
masitinib 6 mg/kg/day; placebo

Multiple Myeloma Clinical Trial using ACY-1215

Acetylon Pharmaceuticals Incorporated - Recruiting 18 years or older.
- A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma.
ACY-1215

Multiple Myeloma Clinical Trial using Total Marrow Irradiation

Ottawa Hospital Research Institute - Recruiting 18 years to 60 years.
- A Dose Escalation Study of Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).
Total Marrow Irradiation

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using bortezomib; hydroxychloroquine; immunologic technique; laboratory biomarker analysis; mass spectrometry; pharmacological study; biopsy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma.
bortezomib; hydroxychloroquine; immunologic technique; laboratory biomarker analysis; mass spectrometry; pharmacological study; biopsy

Multiple Myeloma Clinical Trial using Fluphenazine HCl

Immune Control - Recruiting 18 years or older.
- Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Fluphenazine HCl